109 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
)
For the three months ended
For the nine months ended
September
Revenue
Licensing fees (Note 6)
Expenses
Research and development
General … ,
Research and development
REPLICEL LIFE SCIENCES INC.
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
For the six months ended September
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
and development
General and administrative
Other items
Net loss
Research and Development expenses totalled $390,369 for the nine months ended September … , the Company had current liabilities in excess of current assets of $1,318,864. Additional working capital will be required for research and development
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
)
For the three months ended
For the six months ended
June 30,
Revenue
Licensing fees (Note 6)
Expenses
Research and development
General and administrative … will require additional funding to continue its research and development activities, which may not be available on acceptable terms. This will result
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
.
- 13 -
DISCUSSION OF OPERATIONS
For the six months ended June 30
Variance
Revenue
Expenses
Research and development
General and administrative …
Other items
Total loss
Research and Development expenses totalled $348,816 for the six months ended June 30, 2023, compared to $228,497 for the same
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
Three
months
ended
Dec 31
Change
from
2022 to
Increase/
Percentage
(Decrease)
Change
Revenue
Expenses
Research and development
General … representing an increase of $76,332 or 12%. Research and Development expenses were higher during the three months ended March 31, 2023 than 2022 due
6-K
EX-99.1
gu0gvrlcfw8d
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
gkv38o9ao0
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
wzyjb1abag7j8pngmn
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.1
0zn5gwo4 p4
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
oz2paksvv
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.2
d86k86kiu0owoj
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
73gszdh d0
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.3
mbl4f0p 0zfqh
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
snd txxc13pta6ly
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
sgvpsl7vgj qwesm
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.2
ihxlirs5c cpi3
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
c2yr urzuxtyoeq
12 Oct 21
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
1:06pm
6-K
EX-99.2
291 eg7bt
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm